# Human Rotavirus

## Rotarix 1.5mL/dose oral suspension

| 藥物代碼 | LROT2 |
| :--- | :--- |
| 適應症 | Prevention of gastroenteritis caused by rotavirus, G1 & certain non-G1 serotypes. |
| 副作用 | Irritability, loss of appetite, diarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue. |
| 禁忌 | Hypersensitivity, uncorrected congenital malformation of the GIT, known or suspected immunodeficiency. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | Oral vaccination consisting of 2 doses: 1st dose may be administered from 6-16 weeks after birth. The vaccination course should be completed by 24 weeks after birth. There should be an interval of at least 4 wk between doses. |
| 肝功能異常 | 無需調整劑量  There are no dosage adjustments provided in the manufacturer’s labeling. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## RotaTeq \(MSD\) 2mL/dose

| 藥物代碼 | LROT3 |
| :--- | :--- |
| 適應症 | Prevention of rotavirus gastroenteritis in infant & children caused by the serotypes G1, G2, G3, G4 & G-serotypes that contain P1 \(such as G9\). |
| 副作用 | Diarrhea, vomiting, irritability, fever. |
| 禁忌 | Hypersensitivity. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | Vaccination series: 3 doses administered orally starting at 6-12 weeks of age; the subsequent doses administered at 4- to 10-weeks intervals. The 3rd dose should be given before 32 weeks of age. |
| 肝功能異常 | 無需調整劑量  There are no dosage adjustments provided in the manufacturer’s labeling. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

